文献速递头颈外科

面血管蒂颊肌黏膜瓣重建舌与口底癌缺损的肿瘤学安全性:回顾性多中心病例对照研究

Oncologic Safety of Facial-Vessel-Based Buccinator Myomucosal Flaps for Tongue and Oral Floor Reconstruction: A Retrospective Multicenter Case-Control Study.
PubMed 文献 · Head Neck · 2025-10-23

该回顾性多中心病例对照研究纳入615例cT1-T3 cN0舌/口底鳞癌患者,比较面血管蒂颊肌黏膜瓣(BMF)与游离筋膜皮瓣(FFF)的肿瘤学结局。5年无进展生存率BMF组69.8%对FFF组66.2%,调整HR 0.87(95%CI 0.43-1.78),满足非劣效;局部、区域及远处复发累积发生率两组相似。结论认为保留面动静脉的选择性颈清扫未损害肿瘤学结局,BMF是合适cN0患者中小型缺损的有效选择。

要点

  • BMF与FFF的5年PFS分别为69.8%与66.2%,调整HR 0.87(95%CI 0.43-1.78),满足非劣效。
  • 两组局部、区域及远处复发累积发生率相似,分别为7.5%对8.3%、6.3%对6.1%、2.1%对1.7%。
  • 保留面动静脉的BMF适用于经严格Ⅰ区清扫、无需pull-through切除的合适cN0患者中小型缺损。

核心结论

  • 选择性颈清扫中保留面动静脉未损害肿瘤学结局,面血管蒂BMF是合适cN0舌/口底中小型缺损的有效重建选择。

研究设计与样本

  • 回顾性多中心病例对照研究,纳入cT1-T3 cN0舌/口底鳞状细胞癌患者,BMF组390例、FFF组225例,共615例,基线可比。

主要发现

  • 5年PFS为BMF组69.8%对FFF组66.2%,调整HR(FFF vs. BMF)0.87(95%CI 0.43-1.78),满足非劣效。
  • 5年OS为BMF组77.9%对FFF组73.5%。
  • 复发累积发生率相似:局部7.5%对8.3%,区域6.3%对6.1%,远处2.1%对1.7%。

关键数值与推荐

  • 主要终点为PFS非劣效检验,调整HR(FFF vs. BMF)0.87(95%CI 0.43-1.78)满足非劣效。
  • BMF适用于经严格Ⅰ区清扫且无需pull-through切除的合适cN0患者中小型舌/口底缺损。

临床怎么用

  • 在合适cN0舌/口底中小型缺损患者中,可考虑面血管蒂BMF重建,但需严格Ⅰ区清扫且无需pull-through切除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Buccinator myomucosal flaps (BMFs) have been proposed as a reconstructive solution for defects of the tongue and oral floor; however, their harvest requires preservation of the facial artery and vein. This study aimed to evaluate the oncologic safety of this approach compared with free fasciocutaneous flaps (FFF). METHODS: A retrospective multicenter case-control study including cT1-T3 cN0 tongue/oral floor squamous cell carcinoma was performed. Cases received BMFs while controls received FFFs. The primary endpoint was progression-free survival (PFS) tested for non-inferiority. Secondary endpoints were overall survival (OS), disease-specific survival (DSS), and cumulative incidence of local, regional, and distant recurrence using competing-risk methods. RESULTS: A total of 615 patients (BMF n = 390; FFF n = 225) with comparable baselines were included. Five-year PFS was 69.8% (BMF) versus 66.2% (FFF); adjusted HR (FFF vs. BMF) 0.87 (95% CI: 0.43-1.78), meeting non-inferiority. Five-year OS was 77.9% versus 73.5%. Cumulative incidence of recurrence was similar: local 7.5% versus 8.3%, regional 6.3% versus 6.1%, and distant 2.1% versus 1.7%. CONCLUSIONS: Preservation of the facial artery and vein during selective neck dissection did not compromise oncologic outcomes. Facial-vessel-based BMFs are a valid option for small-to-medium tongue/oral floor defects in appropriately selected cN0 patients when meticulous level I clearance is performed and a pull-through resection is not required.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Vaira LA, Massarelli O, Polesel J, et al. Oncologic Safety of Facial-Vessel-Based Buccinator Myomucosal Flaps for Tongue and Oral Floor Reconstruction: A Retrospective Multicenter Case-Control Study. Head Neck. 2025. PMID: 41127923. doi:10.1002/hed.70082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。